What are the guidelines for pap (Papanicolau test) and HPV (Human Papillomavirus) screening for a 66-year-old female with a history of normal paps and a new partner?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cervical Cancer Screening Guidelines for a 66-Year-Old Woman with Normal Paps and a New Partner

For a 66-year-old woman with normal Pap history and a new partner, cervical cancer screening should be discontinued if she has had adequate prior screening, defined as 3 consecutive negative cytology tests or 2 consecutive negative cotests within the past 10 years, with the most recent test occurring within the past 5 years. 1, 2

Screening Recommendations for Women Over 65

When to Discontinue Screening

  • Women should discontinue cervical cancer screening after age 65 if they have:
    • 3 consecutive negative cytology tests OR
    • 2 consecutive negative cotests (HPV + cytology) within the 10-year period before ceasing screening
    • With the most recent test occurring within the last 5 years 1

When to Continue Screening

Screening should continue beyond age 65 ONLY in these specific circumstances:

  • History of cervical intraepithelial neoplasia grade 2 (CIN2) or more severe diagnosis within the past 20-25 years 1
  • In utero exposure to diethylstilbestrol (DES) 1
  • Immunocompromised status (organ transplantation, chemotherapy, chronic corticosteroid treatment, HIV positive) 1
  • Insufficient documentation of adequate prior screening 1

Important Considerations for This Patient

New Sexual Partner

  • Having a new sexual partner is NOT a reason to continue screening beyond age 65 if the woman has adequate prior negative screening 1
  • The American Cancer Society explicitly states: "Once screening is discontinued, it should not resume for any reason, including if a woman has a new sexual partner." 1

Screening History Documentation

  • If documentation of prior screening is unavailable, screening should continue until criteria for discontinuation are met 1
  • Adequate prior screening is the key determinant, not new sexual partners or sexual activity

Special Considerations

Hysterectomy Status

  • If the patient has had a total hysterectomy with removal of the cervix for benign reasons (not due to CIN2+ or cancer), no screening is needed 1, 2
  • If she has had a subtotal (supracervical) hysterectomy, screening should continue following recommendations for average-risk women 1

History of Abnormal Results

  • Women with a history of CIN2 or more severe diagnosis should continue routine screening for at least 20 years, even if screening extends beyond age 65 1

Screening Methods (If Continued Screening Is Indicated)

For women aged 30-65 years (applicable if screening must continue):

  • Preferred approach: HPV testing alone every 5 years OR
  • HPV and cytology cotesting every 5 years OR
  • Cytology alone every 3 years 1, 3

Common Pitfalls to Avoid

  1. Continuing screening unnecessarily: Many providers continue screening beyond age 65 despite adequate prior negative screening, which can lead to unnecessary procedures, anxiety, and increased healthcare costs 2

  2. Restarting screening due to new sexual partners: This is explicitly not recommended by guidelines 1

  3. Lack of documentation: Ensure proper documentation of screening history before discontinuing screening 1

  4. Overestimating benefits: The benefits of screening women over 65 with adequate prior screening are minimal compared to potential harms 2, 3

By following these evidence-based guidelines, you can provide appropriate care while avoiding unnecessary testing for this 66-year-old patient with normal Pap history and a new partner.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cervical Cancer Screening Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.